Shim Woo-Haing, Suh Sung-Won, Jwa Seung-Wook, Song Margaret, Kim Hoon-Soo, Ko Hyun-Chang, Kim Byung-Soo, Kim Moon-Bum
Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea.
Ann Dermatol. 2013 May;25(2):168-72. doi: 10.5021/ad.2013.25.2.168. Epub 2013 May 10.
There is as yet no effective and safe treatment for vitiligo. One percent pimecrolimus cream, a topical calcineurin inhibitor, has been tried for the treatment of vitiligo, with its therapeutic efficacy having mostly been reported in non-segmental vitiligo. However, questions about the therapeutic efficacy of 1% pimecrolimus cream have remained unanswered regarding segmental vitiligo.
The aim of this study was to study the therapeutic efficacy and safety of 1% pimecrolimus cream for segmental childhood vitiligo.
Nine childhood patients with segmental vitiligo were treated with 1% pimecrolimus cream twice daily for three months, after which good responders were scheduled to continue with the 1% pimecrolimus cream monotherapy. The efficacy and safety of this treatment were determined by the levels of repigmentation, initial response time and the presence of adverse events including burning, dryness, stinging and itching.
Four of nine patients achieved mild to moderate responses after three months of treatment and thus continued with treatment. Among these four patients, three achieved an excellent response and one patient achieved a moderate response, with a mean treatment duration of 7.3 months. Transient local burning sensation was the most common adverse event. In comparison with the patients with poor response, those patients with good response showed a shorter disease duration (8.5±10.5 mo vs. 13.4±10.1 mo), more frequent facial involvement (4/4 patients vs. 3/5 patients) and earlier initial response after treatment (1.0±0.0 mo vs. 2.0±1.0 mo).
This study suggests that 1% pimecrolimus cream is an effective and well-tolerated treatment for segmental childhood vitiligo.
白癜风目前尚无有效且安全的治疗方法。1%吡美莫司乳膏作为一种局部钙调神经磷酸酶抑制剂，已被用于白癜风的治疗，其治疗效果大多在非节段性白癜风中报道。然而，关于1%吡美莫司乳膏治疗节段性白癜风的疗效问题仍未得到解答。
本研究旨在探讨1%吡美莫司乳膏治疗儿童节段性白癜风的疗效和安全性。
9例儿童节段性白癜风患者每天两次外用1%吡美莫司乳膏，持续3个月，之后对疗效良好者继续采用1%吡美莫司乳膏单一疗法。通过色素沉着水平、初始反应时间以及包括烧灼感、干燥、刺痛和瘙痒在内的不良事件的发生情况来确定该治疗方法的疗效和安全性。
9例患者中有4例在治疗3个月后达到轻度至中度反应，因此继续接受治疗。在这4例患者中，3例达到优效反应，1例达到中度反应，平均治疗时间为7.3个月。短暂的局部烧灼感是最常见的不良事件。与反应较差的患者相比，反应良好的患者病程较短（8.5±10.5个月 vs. 13.4±10.1个月），面部受累更频繁（4/4例患者 vs. 3/5例患者），治疗后初始反应更早（1.0±0.0个月 vs. 2.0±1.0个月）。
本研究表明，1%吡美莫司乳膏是治疗儿童节段性白癜风的一种有效且耐受性良好的方法。
